*EMBARGOED All research presented at the 2019 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Monday, October 28, 2019, at 8:00 am CDT.
Oral 6 Statin Use Reduces the Risk of Hepatocellular Carcinoma: An Updated Meta-analysis and Systematic Review
Author Insight from Muhammad Talal Sarmini, MD, Cleveland Clinic Foundation
What’s new here and important for clinicians?
We evaluated 20 studies from Asia, Europe and US that included 2.6 million patients. We found that patients who are taking statins were 43% less likely to have hepatocellular cancer. Given the favorable effects of statins against HCC, they should be considered in patients with increased risk for HCC (cirrhosis, HBV, HCV etc.).
What do patients need to know?
What do patients need to know? Our study found that patients who were taking statins had a lower rate of primary liver cancer which suggests that statins may have a protective role against liver cancer development. Patients with chronic liver diseases need to check with their doctor if they should be on statins.
Muhammad Talal Sarmini, MD, Cleveland Clinic Foundation
sarminm [at] ccf [dot] org
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi [dot] org or by phone at 301-263-9000.